IP Library Granted Patent US 10,538,744
Granted Patent B2
US 10,538,744 · App. 15/452,470 · Granted Jan 21, 2020

Use of adenovirus and nucleic acids coding therefor

Inventor: Per Sonne Holm (Furstenfeldbruck, DE)
C12N7/00A61K35/761A61K35/763C07K14/005C12N15/86A61K38/00A61K48/00C12N2710/10322C12N2710/10332C12N2710/10343C12N2830/00C12N2840/203
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,538,744
App. No.
15/452,470
Granted
Jan 21, 2020
Kind
B2
Abstract

This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.

Claims (9)

1. A method for the treatment of a subject identified to have a cancerous tumor that expresses Y box binding protein 1 (YB-1), the method comprising:

administering to the subject in need thereof an AdΔ24 adenovirus that is replication deficient in cells that lack YB-1 in the nucleus, wherein the adenovirus comprises an E1A protein lacking a functional CR2 domain; and

wherein the cancerous tumor, or a portion thereof, is resistant to at least one pharmacological agent.

2. The method of claim 1 , wherein the virus encodes for YB-1.

3. The method of claim 1 , wherein the cells that form the cancerous tumor, or part thereof, overexpress membrane-bound transport protein P glycoprotein.

4. The method of claim 1 , wherein the E1A protein does not induce nuclear localization of YB-1.

5. The method of claim 4 , wherein the E1A protein is encoded by a gene that is under the control of a tissue and/or tumor specific promoter.

6. The method of claim 2 , wherein the YB-1 is under the control of a tissue and/or tumor specific promoter.

7. The method of claim 1 , wherein the E1A protein transactivates at least one of E1B55 kDa, 4orf3, E4orf6, and E3ADP.

Priority Claims (4)
DE 102 23 534 · May 27, 2002 · national
DE 102 25 400 · Jun 7, 2002 · national
DE 102 48 039 · Oct 15, 2002 · national
DE 103 22 530 · May 19, 2003 · national
Continuity (3)
Division 12769435 · Apr 28, 2010
Continuation 10515238
Related Publication 20180002674A1 · Jan 4, 2018
Cited By (4)
US 12,281,324 US 12,365,878 US 12,514,887 US 12,589,128